July 2024, Roche announced that its oral GLP-1 receptor agonist GLP-1 Agonists Target Patient Pool Analysis: between 2014 and 2018, only In a study by Watanabe et al
"When it comes to GLP-1 medications, safety should always be the top priority
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial
Reporting contributes to national pharmacovigilance and helps build the evidence base for emerging treatments
So if you're suffering from risk factors that increase your chances of compromised glutathione production, or even if you just live in the modern world, don't forget this important molecule
The Medicare GLP-1 Bridge specifically covers the weight management indications, so Ozempic and Mounjaro are not part of the bridge program